TrialThe Lancet. Haematology2021

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Ryan C Lynch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.